Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676699 | 1.00 | MTNR1A (0.48) | MTNR1AMTNR1BESR1KCNH2SIRT2 | |
| SCHEMBL6677141 | 0.89 | ACACB (0.52) | ESR1KCNH2ACACB | |
| SCHEMBL6677138 | 0.89 | ACACB (0.52) | ESR1KCNH2ACACB | |
| SCHEMBL6676771 | 0.86 | ADRB1 (0.43) | ESR1KCNH2ACACB | |
| SCHEMBL6676768 | 0.86 | ADRB1 (0.43) | ESR1KCNH2ACACB | |
| SCHEMBL6682534 | 0.85 | ESR1 (0.46) | ESR1KCNH2ACACB | |
| SCHEMBL6682539 | 0.85 | ESR1 (0.46) | ESR1KCNH2ACACB | |
| SCHEMBL3293355 | 0.84 | TAAR1 (0.52) | MTNR1AMTNR1BESR1KCNH2MEN1 | |
| SCHEMBL1096460 | 0.84 | TAAR1 (0.52) | MTNR1AMTNR1BESR1KCNH2MEN1 | |
| SCHEMBL6804630 | 0.83 | ACACB (0.48) | MTNR1AMTNR1BESR1KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | MTNR1A 245/4885MTNR1B 464/4885ESR1 2525/4885 |
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | MTNR1A 1674/4885MTNR1B 1266/4885ESR1 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.